Highbridge Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

Highbridge Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$248	Hold	1,042	–	–	﹤0.01%	369
2025 Q4	$1.22K	Hold	1,042	–	–	﹤0.01%	289
2025 Q3	$1.58K	Hold	1,042	–	–	﹤0.01%	285
2025 Q2	$2.88K	Hold	1,042	–	–	﹤0.01%	278
2025 Q1	$7.08K	Hold	1,042	–	–	﹤0.01%	235
2024 Q4	$14.4K	Buy	1,042 +521	+100%	+$9.77K	﹤0.01%	285
2024 Q3	$7.13K	Hold	521	–	–	﹤0.01%	318
2024 Q2	$12.5K	Buy	+521	New	+$16.6K	﹤0.01%	301
2023 Q4	–	Sell	-1,042	Closed	-$416K	–	364
2023 Q3	$416K	Hold	1,042	–	–	0.02%	148
2023 Q2	$1.31M	Hold	1,042	–	–	0.06%	121
2023 Q1	$1.28M	Hold	1,042	–	–	0.05%	146
2022 Q4	$1.27M	Hold	1,042	–	–	0.04%	231
2022 Q3	$1.23M	Hold	1,042	–	–	0.02%	336
2022 Q2	$1.24M	Sell	1,042 -3,618	-78%	-$4.31M	0.03%	335
2022 Q1	$5.53M	Sell	4,660 -8,536	-65%	-$10.1M	0.13%	228
2021 Q4	$15.5M	Buy	+13,196	New	+$15.6M	0.34%	94

Other funds holding CLDI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCI

RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Highbridge Capital Management's CLDI Position: Q1 2026 in Review

Highbridge Capital Management held its Calidi Biotherapeutics (CLDI) position steady in Q1 2026 at 1,042 shares worth $248. The position accounts for ﹤0.01% of the portfolio, ranked #369.

Highbridge Capital Management first reported a position in CLDI in Q4 2021 and has held it in 16 quarters since. The position peaked at $15.5M in Q4 2021. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

Highbridge Capital Management held 1,042 shares of Calidi Biotherapeutics worth $248 as of Q1 2026.
Highbridge Capital Management left its Calidi Biotherapeutics share count unchanged in Q1 2026.
Calidi Biotherapeutics made up ﹤0.01% of Highbridge Capital Management's portfolio in Q1 2026, its #369 holding.
Highbridge Capital Management first reported a position in Calidi Biotherapeutics in Q4 2021 and has held it in 16 quarters since.
Highbridge Capital Management's Calidi Biotherapeutics position peaked at $15.5M in Q4 2021.
28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on Highbridge Capital Management's 13F filing for Q1 2026, filed 15 May 2026.